| Journal | iScience |
| Study Type | Clinical Study |
| Population | Human participants |
Neuropathic cancer pain affects up to 40% of cancer patients and survivors, often proving refractory to conventional analgesics. This comprehensive review synthesizes emerging molecular targets that could inform more precise therapeutic approaches for this challenging clinical syndrome.
This review examines the complex pathophysiology of neuropathic cancer pain, distinguishing between tumor-induced and chemotherapy-induced mechanisms. The authors evaluate novel therapeutic modalities including antisense oligonucleotides, nanotechnology-based drug delivery systems, and endocannabinoid system modulation. While comprehensive in scope, this is a narrative review rather than original research, limiting direct clinical applicability. The focus on endocannabinoid pathways aligns with growing clinical interest in cannabis-based interventions for neuropathic pain conditions.
“As a clinician treating cancer patients with neuropathic pain, I find the endocannabinoid pathway discussion particularly relevant given the emerging clinical evidence for cannabinoids in this indication. However, we need controlled trials of these novel approaches before they can meaningfully change practice.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- What is neuropathic cancer pain and how common is it among cancer patients?
- How does the endocannabinoid system potentially help treat neuropathic cancer pain?
- What role does nanotechnology play in treating neuropathic cancer pain?
- How do antisense oligonucleotides work in treating neuropathic pain?
- What is the difference between tumor-induced and chemotherapy-induced neuropathic pain?
FAQ
What is neuropathic cancer pain and how common is it among cancer patients?
Neuropathic cancer pain (NCP) is a complex pain syndrome that severely compromises quality of life for cancer survivors. It can arise from both tumor-induced nerve damage and chemotherapy-induced peripheral neuropathy, representing a significant clinical challenge due to its multifactorial pathogenesis.
How does the endocannabinoid system potentially help treat neuropathic cancer pain?
The endocannabinoid system represents a novel analgesic target for treating neuropathic cancer pain through modulation of pain signaling pathways. This approach offers potential therapeutic benefits by targeting specific molecular mechanisms involved in pain processing, though clinical applications are still being investigated.
What role does nanotechnology play in treating neuropathic cancer pain?
Nanotechnology enables bespoke drug delivery systems that can potentially overcome current therapeutic limitations in treating neuropathic cancer pain. These targeted delivery methods may improve drug efficacy while reducing systemic side effects, representing a promising advancement in pain management strategies.
How do antisense oligonucleotides work in treating neuropathic pain?
Antisense oligonucleotides work by silencing pathological gene expression involved in neuropathic pain pathways. This targeted approach addresses pain at the molecular level by inhibiting specific genes that contribute to pain signaling, offering a precision medicine approach to treatment.
What is the difference between tumor-induced and chemotherapy-induced neuropathic pain?
Tumor-induced neuropathic pain results from direct nerve damage caused by tumor growth and infiltration, while chemotherapy-induced neuropathic pain stems from neurotoxic effects of cancer treatments. Both types involve complex neuro-tumor interactions within the tumor microenvironment, requiring different therapeutic approaches based on their distinct pathogenic mechanisms.